Clinical trial
A Study of LY3209590 in Participants With Type 1 Diabetes
NCT04450407
Study timeline
Study start (actual)2020-07-06Date precision: day
Registry last updated2022-10-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetes Mellitusunresolved
Interventions
LY3209590DRUG
Insulin DegludecDRUG · verified · RxNorm: insulin degludec
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
SevilleSpain2ViennaAustria2HoustonTexas, United States1DallasTexas, United States1AtlantaGeorgia, United States1JacksonvilleFlorida, United States1AuroraColorado, United States1AustinTexas, United States1Las VegasNevada, United States1HamburgGermany1Fort WorthTexas, United States1SyracuseNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04450407 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.